EPO and pulmonary arterial hypertension: In contrast, the increased MIC-1 and EPO levels, both of which downregulate hepcidin expression, cannot explain the high levels of hepcidin in PAH patients and probably reflect adverse cardiac events and hypoxic and/or iron-deficient conditions.